Carbetocin Dosing & Reconstitution Guide
This comprehensive reference outlines the dosing parameters for Carbetocin, a synthetic analog of oxytocin utilized primarily in reproductive and hormonal research. The information provided herein encompasses reconstitution guidelines, dosing ranges, pharmacokinetics, and storage considerations specifically for research applications. It is crucial to note that the data presented is intended for laboratory use only, and not for personal administration. Careful adherence to outlined protocols is essential to ensure accurate dosing and minimize potential errors during experimental procedures.
Dosing Protocol
Carbetocin can be administered either intravenously (IV) or intramuscularly (IM), with the choice of route typically determined by the specific research context. A single dose of 100 mcg is commonly employed in studies examining its efficacy in preventing postpartum hemorrhage. This dosing strategy aligns with findings from clinical trials that have demonstrated the compound's utility in this indication. Researchers should ensure precise measurement and administration to maintain the integrity of experimental results. It is important to emphasize that this dosing information is derived from clinical studies and should not be interpreted as a guideline for personal use.
Timeline & Pharmacokinetics
Research indicates that the onset of action for Carbetocin, when administered intravenously, occurs approximately 2 minutes post-injection. The pharmacokinetic profile reveals a half-life of around 40 minutes, which is significant for understanding the duration of its effects in a research setting. Following administration, a washout period of 3 to 4 hours is suggested, allowing for the clearance of the peptide from the system. This pharmacokinetic data is critical for designing experiments that require precise timing and dosing intervals, particularly in studies assessing the hormone's physiological impacts.
Safety & Contraindications
Commonly reported adverse effects associated with Carbetocin include abdominal pain, uterine cramping, nausea, vomiting, facial flushing, and a sensation of warmth. These effects, while generally considered manageable, underscore the necessity for careful monitoring during research applications. Contraindications are particularly relevant in certain populations; individuals with hypersensitivity to Carbetocin or oxytocin should not be exposed to this compound. Additionally, Carbetocin is contraindicated for use during pregnancy or for labor induction, as its approval is limited to postpartum applications. Limited data is available regarding dose adjustments for patients with hepatic or renal disease, necessitating caution in such cases.
Shop Research Peptides

BPC-157 5mg
5mg

Retatrutide 20mg
20mg

Retatrutide 10mg
10mg

GHK-Cu 50mg
50mg

Tesamorelin 10mg
10mg

BPC-157 10mg
10mg

Tirzepatide 10mg
10mg

KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe